Know Cancer

forgot password

Phase II Study of Faslodex In Recurrent/Metastatic Endometrial Cancer

Phase 2
Open (Enrolling)
Endometrial Cancer

Thank you

Trial Information

Phase II Study of Faslodex In Recurrent/Metastatic Endometrial Cancer


- Compare the probability of clinical response in estrogen receptor (ER)-positive vs
ER-negative patients with recurrent, persistent, or metastatic endometrial cancer
treated with fulvestrant.

- Compare the relationship between response rate and intensity of receptor expression in
patients treated with this drug.

- Determine the frequency and intensity of toxicity of this drug in these patients.

OUTLINE: Patients receive fulvestrant intramuscularly on day 1. Treatment repeats every 28
days for at least 2 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then
annually thereafter.

Inclusion Criteria


- Histologically confirmed recurrent, persistent, or metastatic endometrial cancer that
is not curable with surgery or radiotherapy

- Estrogen receptor (ER) and progesterone receptor status known by immunohistochemistry

- ER positive or negative allowed

- Measurable disease

- At least 1 target lesion not within a previously irradiated field OR irradiated
target lesion with clear disease progression

- At least 20 mm by conventional techniques, including palpation, x-ray, CT scan,
MRI, OR at least 10 mm by spiral CT scan



- Not specified

Performance status:

- GOG 0-1

Life expectancy:

- Not specified


- Absolute neutrophil count ≥ 1,500/mm^3

- Platelet count ≥100,000/mm^3

- No prior bleeding diathesis (disseminated intravascular coagulation, clotting factor
deficiency, or requirement for anticoagulants)


- Bilirubin ≤ 1.5 times upper limit of normal (ULN)

- SGOT ≤ 3 times ULN

- Alkaline phosphatase ≤ 3 times ULN


- Creatinine ≤ 2 mg/dL


- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No hypersensitivity to castor oil

- No other concurrent malignancy except nonmelanoma skin cancer

- No other prior malignancy within past 5 years


Biologic therapy:

- Not specified


- No prior chemotherapy for persistent, recurrent, or metastatic endometrial cancer

- No more than 1 prior chemotherapy regimen for newly diagnosed endometrial cancer that
has subsequently recurred

Endocrine therapy:

- At least 3 weeks since prior hormonal therapy and recovered


- See Disease Characteristics

- At least 3 weeks since prior radiotherapy and recovered


- See Disease Characteristics

- At least 3 weeks since prior surgery and recovered

Type of Study:


Study Design:

Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Clinical response by RECIST criteria evaluated every 8 weeks

Safety Issue:


Principal Investigator

Allan Covens, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Edmond Odette Cancer Centre at Sunnybrook


United States: Federal Government

Study ID:




Start Date:

August 2004

Completion Date:

Related Keywords:

  • Endometrial Cancer
  • stage IV endometrial carcinoma
  • recurrent endometrial carcinoma
  • stage III endometrial carcinoma
  • Endometrial Neoplasms
  • Sarcoma, Endometrial Stromal
  • Adenoma



Mayo Clinic Scottsdale Scottsdale, Arizona  85259
Mayo Clinic - Jacksonville Jacksonville, Florida  32224
Mayo Clinic Cancer Center Rochester, Minnesota  55905
MBCCOP - Hawaii Honolulu, Hawaii  96813
University of Chicago Cancer Research Center Chicago, Illinois  60637
Duke Comprehensive Cancer Center Durham, North Carolina  27710
CCOP - Christiana Care Health Services Wilmington, Delaware  19899
CCOP - Carle Cancer Center Urbana, Illinois  61801
George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus New Britain, Connecticut  06050
Case Comprehensive Cancer Center Cleveland, Ohio  44106-5065
Drexel University College of Medicine - Center City Hahnemann Campus Philadelphia, Pennsylvania  19102
Avera Cancer Institute Sioux Falls, South Dakota  57105
Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center La Crosse, Wisconsin  54601
University of Texas Medical Branch Galveston, Texas  77555-1329
CCOP - Northern Indiana CR Consortium South Bend, Indiana  46601
Holden Comprehensive Cancer Center at University of Iowa Iowa City, Iowa  52242-1002
UMASS Memorial Cancer Center - University Campus Worcester, Massachusetts  01605-2982
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Chapel Hill, North Carolina  27599-7570
Cleveland Clinic Taussig Cancer Center Cleveland, Ohio  44195
Fletcher Allen Health Care - University Health Center Campus Burlington, Vermont  05401
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences Little Rock, Arkansas  72205
Hulston Cancer Center at Cox Medical Center South Springfield, Missouri  65807
St. John's Regional Health Center Springfield, Missouri  65804
Carol G. Simon Cancer Center at Morristown Memorial Hospital Morristown, New Jersey  07962
SUNY Downstate Medical Center Brooklyn, New York  11203
Cancer Care Associates - Midtown Tulsa Tulsa, Oklahoma  74104
Women and Infants Hospital of Rhode Island Providence, Rhode Island  02905
Wake Forest University Comprehensive Cancer Center Winston-Salem, North Carolina  27157-1096
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas Dallas, Texas  75390
Battle Creek Health System Cancer Care Center Battle Creek, Michigan  49017
Riverside Methodist Hospital Cancer Care Columbus, Ohio  43214
Jonsson Comprehensive Cancer Center at UCLA Los Angeles, California  90095-1781
MBCCOP - Medical College of Georgia Cancer Center Augusta, Georgia  30912-3730
Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center Savannah, Georgia  31403-3089
Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana  46202-5289
University of Mississippi Cancer Clinic Jackson, Mississippi  39216-4505
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School New Brunswick, New Jersey  08903
Oklahoma University Cancer Institute Oklahoma City, Oklahoma  73104
M. D. Anderson Cancer Center at University of Texas Houston, Texas  77030-4009
Methodist Estabrook Cancer Center Omaha, Nebraska  68114-4199
Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center Orange, California  92868
Robert H. Lurie Comprehensive Cancer Center at Northwestern University Chicago, Illinois  60611
Todd Cancer Institute at Long Beach Memorial Medical Center Long Beach, California  90801
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center Hartford, Connecticut  06105
Hope A Women's Cancer Center Asheville, North Carolina  28801
Mount Carmel Health - West Hospital Columbus, Ohio  43222
Rosenfeld Cancer Center at Abington Memorial Hospital Abington, Pennsylvania  19001
Fox Chase Cancer Center - Philadelphia Philadelphia, Pennsylvania  19111-2497
David L. Rike Cancer Center at Miami Valley Hospital Dayton, Ohio  45409
Moses Cone Regional Cancer Center at Wesley Long Community Hospital Greensboro, North Carolina  27401
McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center Reading, Pennsylvania  19612-6052
Louisville Oncology at Norton Cancer Institute - Louisville Louisville, Kentucky  40202